Raadpleeg ook literatuurlijsten niet-toxische middelen en behandelingen van arts-bioloog drs. Engelbert Valstar

7 november 2019: U zou de natuurapotheek kunnen raadplegen hoe en welke Chinese kruiden te gebruiken zijn bij uw vorm van kanker of ziekte.

Wij hebben ook wel het adres van de producent in China van de Sqenqi Fuzheng injecties waar u het via een arts of apotheker kunt bestellen, maar lijkt ons beter dat u dit toch doet via een goed gekwalificeerd arts. Het patent voor Kanglaite berust bij deze producent Kanglaite Patent, USA

Zie ook in gerelateerde artikelen meer artikelen over TCM - Traditionele Chinese Medicijnen / Kruiden

14 april 2019: Bron: . 2017 Aug; 24(4): e269–e276

Wanneer patienten met niet-kleincellige longkanker na de chemokuren geen progressie van hun ziekte laten zien en als onderhoudsbehandeling TCM - Traditionele Chinese Kruiden blijven gebruiken dan heeft dat een groot effect (statistisch significant) op de tijd van progressievrije ziekte (hr: 0.66; 95% ci: 0.51 to 0.84; p = 0.001), op de overall overleving (hr: 0.49; 95% ci: 0.35 to 0.68; p < 0.001) en op de kwaliteit van leven (rr: 0.68; 95% ci: 0.61 to 0.75; p < 0.001). Blijkbaar werken TCM ook zonder chemo of andere behandeling bij niet-kleincellige longkanker in het voorkomen van een recidief en zonder de bijwerkingen van chemo. Maar het is al veel vaker aangetoond ook bij andere vormen van kanker dat TCM - Traditionele Chinese Kruiden hetzelfde of soms zelfs beter therapeutisch effect hebben dan chemo.   

Dat blijkt uit een meta-analyse van 16 gerandomiseerde studies bij totaal 1150 patiënten met niet-kleincellige longkanker. Figure 1 en Table i tonen details van de studieselectie. 

De conclusie van deze meta analyse: 

For patients whose evaluations after first-line chemotherapy indicated non-progression (including stable disease, partial response, or complete response), including those with poor qol, use of oral TCM could be considered an efficient and safe maintenance therapy.

In de studie wordt gedetailleerd beschreven hoe de onderzoekers tot deze conclusie komen en uit welke studies. Hier de grafiek van de studies die de overall overleving hebben gemeten:

An external file that holds a picture, illustration, etc.
Object name is conc-24-e269f2.jpg

Meta-analysis (Forest plot) of sixteen studies assessing survival in patients with advanced non-small-cell lung cancer, comparing oral Chinese herbal medicine–based maintenance treatment alone with any of best supportive care, observation, or placebo. (A) Overall survival. (B) Progression-free survival. (C) One-year survival. (D) Two-year survival. hr = hazard ratio; CI = confidence interval; TCM = Traditional Chinese Medicine.

Het volledige studierapport: Oral Chinese herbal medicine as maintenance treatment after chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis is gratis in te zien.

Hier het abstract van de studie met bijbehorende referentielijst:

For patients who show non-progression—including stable disease, partial response, or complete response—after first-line chemotherapy, including those with poor quality of life, oral Chinese herbal medicine can be considered an efficient and safe maintenance therapy strategy.

. 2017 Aug; 24(4): e269–e276.
Published online 2017 Aug 31. doi: 10.3747/co.24.3561
PMCID: PMC5576466
PMID: 28874897

Oral Chinese herbal medicine as maintenance treatment after chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis

Q. Wang, MD,*†,a Q. Wang, MD,‡,a S.F. Wang, MD,§,a L.J. Jiao, MD,* R.X. Zhang, PhD, Y. Zhong, MD, J. Zhang, MD,§ and L. Xu, MD*

Abstract

Background

The concept of maintenance therapy in cancer treatment is currently under debate because of modest survival benefits, added toxicity, economic considerations, and quality-of-life concerns. Traditional Chinese Medicine (tcm) is widely used in China for cancer patients, offering the advantages of low toxicity and enhancement of quality of life. However, no systematic reviews or meta-analyses have assessed the role of tcm as maintenance treatment for non-small-cell lung carcinoma.

Methods

We searched the Chinese Biomedical Literature Database, the China National Knowledge Infrastructure, PubMed, embase, and the Cochrane Library databases for all eligible studies. The endpoints were overall survival (os), progression-free survival (pfs), the 1-year and 2-year survival rates, and performance status. Our meta-analysis used a fixed-effects model and a random-effects model for heterogeneity in the Stata software application (version 11.0: StataCorp LP, College Station, TX, U.S.A.), with the results expressed as hazard ratios (hrs) or risk ratios (rrs), with their corresponding 95% confidence intervals (95% cis).

Results

Sixteen randomized studies representing 1150 patients met the inclusion criteria. Compared with best supportive care, observation, or placebo, tcm as maintenance treatment was associated with a significant increase in os (hr: 0.49; 95% ci: 0.35 to 0.68; p < 0.001), pfs (hr: 0.66; 95% ci: 0.51 to 0.84; p = 0.001), and 2-year survival rate (rr: 0.63; 95% ci: 0.44 to 0.92, p = 0.017), and a significant improvement in performance status (rr: 0.68; 95% ci: 0.61 to 0.75; p < 0.001).

Conclusions

For patients who show non-progression—including stable disease, partial response, or complete response—after first-line chemotherapy, including those with poor quality of life, oral Chinese herbal medicine can be considered an efficient and safe maintenance therapy strategy.

ACKNOWLEDGMENTS

This study was funded by the Shanghai Minhang Municipal Planning Commission of Science and Research Fund (no. 2014MW24); the National Natural Science Fund (no. 81072740); the National Scientific Research Project of National Traditional Chinese Medicine (no. 201307006); the Science and Technology Commission of Shanghai Municipality (nos. 16401970700, 16401970701, 16401970704); and the Fund of Shanghai University of Traditional Chinese Medicine (no. 2015YSN37).

CONFLICT OF INTEREST DISCLOSURES

We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare that we have none.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30. doi: 10.3322/caac.21387. [PubMed] [CrossRef] []
2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32. doi: 10.3322/caac.21338. [PubMed] [CrossRef] []
3. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in globocan 2012. Int J Cancer. 2015;136:359–86. doi: 10.1002/ijc.29210. [PubMed] [CrossRef] []
4. Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA. 2004;92:70–84. [PubMed] []
5. Zarogoulidis K, Zarogoulidis P, Darwiche K, et al. Treatment of non–small cell lung cancer (nsclc) J Thorac Dis. 2013;5(suppl 4):389–96. [PMC free article] [PubMed] []
6. Brodowicz T, Krzakowski M, Zwitter M, et al. on behalf of the Central European Cooperative Oncology Group Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non–small cell lung cancer: a phase iii trial. Lung Cancer. 2006;52:155–63. doi: 10.1016/j.lungcan.2006.01.006. [PubMed] [CrossRef] []
7. Pérol M, Chouaid C, Pérol D, et al. Randomized, phase iii study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2012;30:3516–24. doi: 10.1200/JCO.2011.39.9782. [PubMed] [CrossRef] []
8. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374:1432–40. doi: 10.1016/S0140-6736(09)61497-5. [PubMed] [CrossRef] []
9. Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (paramount): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13:247–55. doi: 10.1016/S1470-2045(12)70063-3. [PubMed] [CrossRef] []
10. Paz-Ares LG, de Marinis F, Dediu M, et al. paramount: final overall survival results of the phase iii study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31:2895–902. doi: 10.1200/JCO.2012.47.1102. [PubMed] [CrossRef] []
11. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. on behalf of the saturn investigators Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11:521–9. doi: 10.1016/S1470-2045(10)70112-1. [PubMed] [CrossRef] []
12. Westeel V, Quoix E, Moro-Sibilot D, et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2005;97:499–506. doi: 10.1093/jnci/dji096. [PubMed] [CrossRef] []
13. Zhang L, Ma S, Song X, et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (inform; c-tong 0804): a multicentre, double-blind randomised phase 3 trial. Lancet. 2012;13:466–75. doi: 10.1016/S1470-2045(12)70117-1. [PubMed] [CrossRef] []
14. Wang SF, Wang Q, Jiao LJ, et al. Astragalus-containing Traditional Chinese Medicine, with and without prescription based on syndrome differentiation, combined with chemotherapy for advanced non-small-cell lung cancer: a systemic review and meta-analysis. Curr Oncol. 2016;23:188–95. doi: 10.3747/co.23.2920. [PMC free article] [PubMed] [CrossRef] []
15. Xu W, Yang G, Xu Y, et al. The possibility of Traditional Chinese Medicine as maintenance therapy for advanced non–small cell lung cancer. Evid Based Complement Alternat Med. 2014:278917. [PMC free article] [PubMed] []
16. Hsiao WL, Liu L. The role of traditional Chinese herbal medicines in cancer therapy—from tcm theory to mechanistic insights. Planta Med. 2010;76:1118–31. doi: 10.1055/s-0030-1250186. [PubMed] [CrossRef] []
17. Lin HS, Zhang Y. Evidence-based medical study of Traditional Chinese Medicine on non-small-cell lung cancer Shi Jie Ke Xue Ji Shu: Zhong Yi Yao Xian Dai Hua. 2008;10:121–5. [DOI: https://doi.org/10.3969/j.issn.1674-3849.2008.04.026] []
18. Ren SR, Liao DB, Zhou XQ, Wang J. Shen Qi Fu Zheng injection combined with radiotherapy in treating 34 elderly advanced non-small-cell lung cancer patients Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006;26:876. [DOI: https://doi.org/10.3321/j.issn:1003-5370.2006.10.028] []
19. Cai HB, Dai FG, Min QF, Shi M, Liao JX, Luo RC. Clinical study of the effects of radiotherapy in combination with Traditional Chinese Medicine on non–small cell lung cancer Di Yi Jun Yi Da Xue Xue Bao. 2001;22:1112–14. [PubMed] []
20. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12. doi: 10.1016/0197-2456(95)00134-4. [PubMed] [CrossRef] []
21. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. doi: 10.1186/1745-6215-8-16. [PMC free article] [PubMed] [CrossRef] []
22. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101. doi: 10.2307/2533446. [PubMed] [CrossRef] []
23. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34. doi: 10.1136/bmj.315.7109.629. [PMC free article] [PubMed] [CrossRef] []
24. Li J. A clinical comparative study of Traditional Chinese Medicine serving as consolidation treatment in patients with advanced non-small-cell lung cancer Zhongguo Fei Ai Za Zhi. 2007;10:520–2. [Available online at: http://kns.cnki.net/KCMS/detail/detail.aspx?filename=faiz200706016&dbname=CJFD&dbcode=CJFQ; cited 9 July 2017] [PubMed] []
25. Liu Z, Yu Z, Ouyang X, et al. Effects of Feitai capsule on progression-free survival in patients with advanced non-small-cell lung cancer Chinese Journal of Clinical Oncology. 2009;4:344–6. [DOI: http://dx.chinadoi.cn/10.3969/j.issn.1009-0460.2009.04.014] []
26. Zhang W, Tang W, Zhang B, et al. Qingfei Xiaoyu decoction in the consolidation treatment of advanced non-small-cell lung cancer: clinical observation of 32 cases Journal of New Chinese Medicine. 2010;12:70–1. [Available online at: http://kns.cnki.net/KCMS/detail/detail.aspx?filename=rend201012039&dbname=CJFD&dbcode=CJFQ; cited 9 July 2017] []
27. Chai X, Yang G, Li Z, et al. The effect on overall survival of Xiaojiyin maintenance treatment for advanced non-small-cell lung cancer Shizhen Guo Yi Guo Yao. 2011;10:2547–8. []
28. Yang G, Li Z, Tao W. Clinical observation of Hebi tablets in maintenance therapy of advanced non-small cell lung cancer Zhong Liu Fang Zhi Yan Jiu. 2011;10:1170–2. [Available online at: http://d.wanfangdata.com.cn/Periodical/zlfzyj201110020; cited 7 July 2017] []
29. Zou Z. Efficacy of Fuzheng Kangai decoction as a maintenance treatment in advanced non-small-cell lung cancer [thesis, Chinese] Guangzhou, Guangdong Province, P.R.C.: Guangzhou University of Chinese Medicine; 2011. p. 60. [Available online at: http://cdmd.cnki.com.cn/article/cdmd-10572-1011136251.htm; cited 7 July 2017] []
30. Yu ZY, Liu ZZ, Ouyou Xiu XN, et al. Effect of Feitai capsule on quality of life and progression-free survival of patients with unresectable non–small cell lung cancer. Chin J Integr Med. 2012;18:106–11. doi: 10.1007/s11655-012-0994-1. [PubMed] [CrossRef] []
31. Liang J, Zhang L. Survival effect of Rongyan capsule, a maintenance treatment for advanced non-small-cell lung cancer Sichuan Zhong Yi. 2013;1:100–1. [Available online at: http://www.cqvip.com/QK/95258X/201301/44633521.html; cited 7 July 2017] []
32. Yang C. Adjuvant chemotherapy and maintenance therapy with Fuzheng decoction in the treatment of advanced non-small-cell lung cancer China Journal of Chinese Medicine. 2013;28:1782–4. [Available online at: http://d.wanfangdata.com.cn/Periodical/henzyxyxb201312004; cited 7 July 2017] []
33. Zeng DX, Bi YZ, Sheng GF, Dong YZ, Song HL. Effectiveness and safety of single-agent ginsenoside Rg3 maintenance therapy after response to first-line chemotherapy in patients with advanced non-small cell lung cancer. Oncology Progress. 2013;6:554–7. [Available online at: http://en.cnki.com.cn/Article_en/CJFDTOTAL-AZJZ201306015.htm; cited 7 July 2017] []
34. Huang B, Zha Q, Zhou Z. Fuzheng decoction as maintenance treatment after chemotherapy in 43 cases of advanced non-small-cell lung cancer Zhongguo Shi Yan Fang Ji Xue Za Zhi. 2014;8:210–13. [Available online at: http://kns.cnki.net/KCMS/detail/detail.aspx?filename=zsfx201408062&dbname=CJFD&dbcode=CJFQ; cited 7 July 2017] []
35. Shao H, Chen J. Prospective study on the therapeutic effect of compound cantharide capsules in the maintenance treatment of advanced lung cancer Chinese Journal of Traditional Chinese Medicine and Pharmacy. 2014;3:686–8. [Available online at: http://kns.cnki.net/KCMS/detail/detail.aspx?filename=zyhs201403092&dbname=CJFD&dbcode=CJFQ; cited 7 July 2017] []
36. Jiliang Gao. Observation of 31 cases of non-small-cell lung cancer receiving maintenance treatment with Shashen Maidong decoction after chemotherapy Zhejiang Journal of Traditional Chinese Medicine. 2016;50:90–1. [Available online at: http://d.wanfangdata.com.cn/Periodical/zjzyzz201502008; cited 7 July 2017] []
37. Liu LS, Liu JX, Shen LP, Jiang Y, Gu AQ. Effect of tcm syndrome differentiation on consolidation treatment in advanced non-small-cell lung cancer Chinese Journal of Traditional Chinese Medicine. 2015;17:1473–8. [Available online at: http://kns.cnki.net/KCMS/detail/detail.aspx?filename=zzyz201517015&dbname=CJFD&dbcode=CJFQ; cited 7 July 2017] []
38. Tian J, Xiao J, Wu H. Supplementing qi and nourishing yin as a maintenance treatment in non-small-cell lung cancer. Jilin Traditional Chinese Medicine. 2015;9:904–6. [Available online at: http://d.wanfangdata.com.cn/Periodical/jlzyy201509012; cited 7 July 2017] []
39. Han Y, Wang H, Xu W, et al. Chinese herbal medicine as maintenance therapy for improving the quality of life for advanced non–small cell lung cancer patients. Complement Ther Med. 2016;24:81–9. doi: 10.1016/j.ctim.2015.12.008. [PubMed] [CrossRef] []
40. Wang J, Chen YL, Ping C. Clinical observations on treating 40 cases of locally advanced non-small-cell lung cancer with the Zilongjin tablet. Chinese Journal of Traditional Chinese Medicine. 2016;8:15–17. [Available online at: http://kns.cnki.net/KCMS/detail/detail.aspx?filename=zyly201601005&dbname=CJFD&dbcode=CJFQ; cited 7 July 2017] []
41. Jalal SL, Ademuyiwa FO, Hanna NH. The role of maintenance chemotherapy in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2009;21:110–15. doi: 10.1097/CCO.0b013e328322cf49. [PubMed] [CrossRef] []
42. Jiang Y, Liu LS, Shen LP, et al. Traditional Chinese Medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: a randomized controlled trial. Complement Ther Med. 2016;24:55–62. doi: 10.1016/j.ctim.2015.12.006. [PubMed] [CrossRef] []
43. Chen YZ, Li ZD, Gao F, Zhang Y, Sun H, Li PP. Effects of combined Chinese drugs and chemotherapy in treating advanced non–small cell lung cancer. Chin J Integr Med. 2009;15:415–19. doi: 10.1007/s11655-009-0415-2. [PubMed] [CrossRef] []
44. Li SG, Chen HY, Ou-Yang CS, et al. The efficacy of Chinese herbal medicine as an adjunctive therapy for advanced non–small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2013;8:e57604. doi: 10.1371/journal.pone.0057604. [PMC free article] [PubMed] [CrossRef] []
45. Konkimalla VB, Efferth T. Evidence-based Chinese medicine for cancer therapy. J Ethnopharmacol. 2008;116:207–10. doi: 10.1016/j.jep.2007.12.009. [PubMed] [CrossRef] []
46. Flower A, Witt C, Liu JP, Ulrich-Merzenich G, Yu H, Lewith G. Guidelines for randomised controlled trials investigating Chinese herbal medicine. J Ethnopharmacol. 2012;140:550–4. doi: 10.1016/j.jep.2011.12.017. [PubMed] [CrossRef] []
47. Tang WR, Yang SH, Yu CT, et al. Long-term effectiveness of combined treatment with traditional Chinese medicine and Western medicine on the prognosis of patients with lung cancer. J Altern Complement Med. 2016;22:212–22. doi: 10.1089/acm.2015.0214. [PMC free article] [PubMed] [CrossRef] []

Articles from Current Oncology are provided here courtesy of Multimed Inc

Plaats een reactie ...

Reageer op "Onderhoudsbehandeling met TCM - Chinese kruiden na chemotherapie bij longkanker geeft significant betere overall overleving en veel betere kwaliteit van leven"


Gerelateerde artikelen
 

Gerelateerde artikelen

Onderhoudsbehandeling met >> TCM - Traditionele Chinese >> TCM - Traditionele Chinese >> Aanvullende niet toxische >> Chinese kruiden naast chemo >> Feitai capsule maakt dat patiënten >> Feitai capsule met een mix >> Significante verbetering van >> TCM = Traditionele Chinese >> Chinese kruidencapsule (ZC >>